About: Late‐onset severe pneumonia after allogeneic hematopoietic stem cell transplantation: prognostic factors and treatments

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Late‐onset severe pneumonia after allogeneic hematopoietic stem cell transplantation: prognostic factors and treatments Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Late‐onset severe pneumonia after allogeneic hematopoietic stem cell transplantation: prognostic factors and treatments
Creator	Chen, H Wang, Y Huang, Xiao-Jun Chen, Y.-H Wang, J.-Z Han, W Huang, X.-J Liu, K.-Y Mo, X.-D Wang, F.-R Xu, L.-P Yan, C.-H Zhang, X.-H
Source	Medline; PMC
abstract	BACKGROUND: In this study, we aimed to evaluate the prognostic factors associated with and treatments for late‐onset severe pneumonia (LOSP) in patients who underwent allogeneic hematopoietic stem cell transplantation (allo‐HSCT). METHODS: Fifty consecutive patients who underwent non‐T‐cell‐depleted allo‐HSCT at the Peking University Institute of Hematology and met the criterion of LOSP after allo‐HSCT were enrolled. RESULTS: The median time from allo‐HSCT to the occurrence of LOSP was 231 (90–1487) days. Twenty‐eight patients harbored 1 or more pathogens (infectious LOSP, I‐LOSP), whereas 22 did not harbor any pathogens (non‐infectious LOSP, NI‐LOSP). The 100‐day survival rate of LOSP patients was 31.1%. Patients smoking before allo‐HSCT (0% vs. 35.4%, P = 0.002) and male gender (20.0% vs. 61.9%, P = 0.026) had lower 100‐day survival rate. Patients with a lower bronchoalveolar lavage fluid (BALF) neutrophil percentage had higher 100‐day survival rate relative to those with higher BALF neutrophil percentage (45.5% vs. 16.7%, P = 0.012). The 100‐day survival rate of patients with I‐LOSP was lower than that of patients with NI‐LOSP (19.1% vs. 46.9%, P = 0.043). Patients given late (≥1 week after LOSP diagnosis) and low‐dose methylprednisolone (MP) therapy (≤2 mg/kg/day) had the best 100‐day survival rate. In the multivariate analysis, nonsmoking before allo‐HSCT and late and low‐dose MP therapy were significantly associated with a better survival after LOSP. CONCLUSION: LOSP is a severe complication after allo‐HSCT. The correct timing and corticosteroid dosage in the context of broad‐spectrum antimicrobial therapy might further improve the outcomes of patients with LOSP.
has issue date	2016-08-02(xsd:dateTime)
bibo:doi	10.1111/tid.12553
bibo:pmid	27218435
has license	no-cc
sha1sum (hex)	77fbd68252a7d914d2ab7cb7c79871296f7027cb
schema:url	https://doi.org/10.1111/tid.12553
resource representing a document's title	Late‐onset severe pneumonia after allogeneic hematopoietic stem cell transplantation: prognostic factors and treatments
has PubMed Central identifier	PMC7169772
has PubMed identifier	27218435
schema:publication	Transpl Infect Dis
resource representing a document's body	covid:77fbd68252a7d914d2ab7cb7c79871296f7027cb#body_text
is schema:about of	named entity 'male' named entity 'All rights reserved' named entity 'broadspectrum' named entity 'Patients' named entity 'allogeneic' named entity '1487' named entity 'BACKGROUND' named entity 'patients' named entity 'corticosteroid' named entity 'late' named entity 'study' named entity 'BALF' named entity 'allogeneic' named entity 'Hematology' named entity 'survival' named entity 'factors' named entity 'smoking' named entity 'Twenty-eight' named entity '2016' named entity 'context' named entity 'evaluate' named entity 'week' named entity 'complication' named entity 'survival rate' named entity 'corticosteroid' named entity 'neutrophil' named entity 'severe pneumonia' named entity 'BALF' named entity 'survival rate' named entity 'low-dose' named entity 'pathogens' named entity 'allogeneic hematopoietic stem cell transplantation' named entity 'prognostic' named entity 'smoked' named entity 'clinical outcomes' named entity 'heterogeneity' named entity 'corticosteroid therapy' named entity 'Chlamydia pneumoniae' named entity 'mechanical ventilation' named entity 'infection' named entity 'France' named entity 'CT examinations' named entity 'HSCT' named entity 'BALF' named entity 'P-values' named entity 'treat patients' named entity 'broad-spectrum antimicrobial' named entity 'bronchoalveolar lavage' named entity 'long-term' named entity 'BALF' named entity 'immune cell' named entity 'BALF' named entity 'proinflammatory cytokine' named entity 'EBV' named entity 'infection control' named entity 'cytology' named entity 'prophylaxis' named entity 'pulmonary complications' named entity 'micafungin' named entity 'virus' named entity 'thrombocytopenia' named entity 'Staphylococcus epidermidis' named entity 'severe pneumonia' named entity 'Clinical outcomes' named entity 'Illinois' named entity 'micafungin' named entity 'corticosteroid therapy' named entity 'cyclosporine' named entity 'clinical findings'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software